



NCTN Skin Cancer Trials Portfolio (Open as of 5/15/2024)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



Cross-disease trials:



NCTN Skin Cancer Trials (Open as of 5/15/2024)

| Protocol Number | Phase | Protocol Title |
|------------------|--------|--|
| A091903 | II | A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma |
| EA6141 | II/III | Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma |
| EA6174 | III | STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial |
| EA6192 | II | A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop) |
| EA6194 | II | Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study |
| S2000 | II | A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases |
| S2015 | III | Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma |
| S2101 | II | Biomarker Stratified Cabozantinib (NSC#761968) and Nivolumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study |
| EAY191 | Other | Molecular Analysis for Combination Therapy Choice (ComboMATCH) |
| EAY191-A3 | II | Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial |
| EAY191-E4 | II | Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial |
| EAY191-E5 | II | A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial |
| EAY191-N5 | II | A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial |
| EAY191-S3 | II | Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial |